Can we use biomarkers and functional assays to implement personalized therapies in transplantation?
Research in transplantation focuses on minimizing immunosuppression to decrease side effects and costs. Indeed, in some patients, partial or complete cessation of immunosuppression is successful, but currently we have no means of identifying suitable patients a priori. Current withdrawal protocols, which do not implement surrogate markers, carry a significant risk of graft injury. To minimize the risk, immune monitoring strategies are required. Here, we review recently described biomarkers and assays, which might enable identification of patients suitable for partial or complete weaning and patients at risk of rejection. The predictive power of these parameters has to be tested in prospective multicenter trials.
Sawitzki
Birgit
B
Institute of Medical Immunology, Campus Charité Mitte, Charite University Medicine, Berlin, Germany. birgit.sawitzki@charite.de
Pascher
Andreas
A
Babel
Nina
N
Reinke
Petra
P
Volk
Hans-Dieter
HD
D001323:Autoantibodies / Q000032:analysis; D015415:Biomarkers / Q000032:analysis*; D015870:Gene Expression; D005786:Gene Expression Regulation; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007206:Individuality; D016030:Kidney Transplantation / Q000276:immunology*; D015166:Monitoring, Immunologic / Q000379:methods*; D014181:Transplantation Immunology; D023001:Transplantation Tolerance / Q000276:immunology
D001323:Autoantibodies; D015415:Biomarkers; D006680:HLA Antigens; D007166:Immunosuppressive Agents